Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

amatsi IG cover

Infographics 28 Nov 2018

Infographic: The Next Big Thing in Biological Drug Delivery

By the year 2022, half of the top 100 drug sales will be biologics. And with 2,700 biologics currently in development, the market will soon be booming. But there is a hitch: Most biological drugs are administered parenterally. And though this is better than nothing, it does coincide with high treatment costs and stress for […]

November 28, 2018 - 1 minutemin - By External Contributor

orphazyme rare disease lysosome DNA

Interview 28 Nov 2018

Navigating the Rare Disease Space: Insights from a Danish CEO

Developing drugs for rare diseases is a tough nut for biotech companies to crack. Labiotech’s Helen Albert interviewed the CEO of the Danish company Orphazyme, Anders Hinsby, at the recent BIO-Europe conference in Copenhagen, who told her about the appeals and challenges of making it in the rare disease space. Traditionally, the low number of […]

November 28, 2018 - 5 minutesmins - By Jonathan Smith

Septic shock news adrenomed header

News and Trends 27 Nov 2018

Berlin Biotech Raises €24M to Progress Septic Shock Candidate to Clinic

Adrenomed closed a €24M Series D round to fund further development of its antibody drug that treats septic shock by preventing excessive fluid loss and preserving the blood vessel walls. Wellington Partners and HBM Healthcare Investments, who specialize in investing in life science companies, joined existing shareholders to lead the fundraising round. Sepsis and resulting […]

November 27, 2018 - 3 minutesmins - By Helen Albert

vectura asthma inhaler

News and Trends 26 Nov 2018

Smart Asthma Inhaler Fails Phase III

It is bad news for asthma sufferers, as a UK biotech has abandoned the development of its smart inhaler after finding that it was no better than placebo in a Phase III trial. Over 52 weeks of treatment, the company Vectura tested whether the inhaler reduced the worsening of asthma symptoms, such as wheezing and […]

November 26, 2018 - 2 minutesmins - By Jonathan Smith

Luxturna gene therapy blindness Europe

News and Trends 26 Nov 2018

First Gene Therapy for Inherited Blindness Approved in Europe

Novartis has received approval for Luxturna, a gene therapy that can restore vision in people with a specific genetic mutation that causes progressive vision loss. The therapy is indicated for people with mutations in the two copies of a gene, called RPE65, that cause retinal cells to die over time, resulting in progressive loss of […]

November 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 28 at 4.10.34 PM e1480345934426

News and Trends 25 Nov 2018

Would You Wear Human Leather with ‘Designer DNA’?

Artist Tina Gorjanc is working on a human leather collection that aims to highlight the shortcomings of laws that allow human biological material to be marketed without permission. Gorjanc has projected a whole fashion line, labeled ‘Pure Human’, that includes jackets and handbags made with lab-grown skin from the renowned fashion designer Alexander McQueen. Originally […]

November 25, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

den bosch netherlands lava therapeutics cancer immunotherapy

Startup Scout 23 Nov 2018

This Biotech Arms Tumor-Busting Cells to Treat Cancer

In the medieval city of ‘s-Hertogenbosch, the Netherlands, Lava Therapeutics is developing a cancer immunotherapy that arms a rare type of immune cell called gamma delta T cells. Mission: Develop antibodies that recruit innate immune cells near tumors and activate them to kill cancer cells. T cells are immune cells that have a strong potential […]

November 23, 2018 - 3 minutesmins - By Jonathan Smith

sobi novimmune rare disease small

More News! 22 Nov 2018

First Drug for Rare Inflammation Syndrome Approved by FDA

The FDA has approved the first drug for the treatment of a rare condition in which the body produces too many active immune cells, developed in a Swiss-Swedish partnership. The antibody drug, emapalumab, is approved to treat primary hemophagocytic lymphohistiocytosis. This condition is a rare, often fatal syndrome in which the immune system produces too […]

November 22, 2018 - 2 minutesmins - By Jonathan Smith

leo pharma pellepharm skin cancer

News and Trends 21 Nov 2018

Leo Pharma Enters Partnership to Develop Topical Treatment for Rare Skin Cancer

The Danish company Leo Pharma and the US biotech PellePharm have joined forces to develop a topical treatment for rare forms of skin cancer. In the partnership, dermatology specialist Leo Pharma is paying PellePharm €61M. This is to fund a Phase III trial of PellePharm’s topical drug to treat the skin cancer Gorlin syndrome, which has no […]

November 21, 2018 - 2 minutesmins - By Jonathan Smith

human microbiome challenges

In Depth 21 Nov 2018

5 Challenges to Unlocking the Real Potential of the Human Microbiome

The study of the human microbiome — the microorganisms living in our body — is a very young field of research that is making big promises to treat all sorts of human diseases. As we get close to the approval of the first treatment based on microbiome science, it’s important to be aware of the […]

November 21, 2018 - 9 minutesmins - By Clara Rodríguez Fernández

valneva emergent tropical zika small

More News! 20 Nov 2018

Phase I Gives Hope for First Zika Vaccine

Results from a Phase I trial showed promising safety and efficacy of a potential first vaccine against the mosquito-borne Zika virus, developed by French biotech Valneva and US biopharma Emergent BioSolutions. In the US-based Phase I trial, 67 participants were injected with either placebo or inactivated forms of the virus as a vaccine. Two months later, […]

November 20, 2018 - 2 minutesmins - By Jonathan Smith

Stilla Technologies DNA quantification

News and Trends 20 Nov 2018

French Firm Gets Funding to Sell More Precise DNA Quantification System

Paris-based Stilla Technologies has raised €16M in a Series A round to sell and develop a high-precision PCR system for DNA quantification with promising applications in diagnostics. The substantial round was led by Illumina Ventures, the investor arm of the gene sequencing giant Illumina. With the funds, Stilla Technologies plans to accelerate sales of its […]

November 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT